<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329769</url>
  </required_header>
  <id_info>
    <org_study_id>PRO044-CLIN-02</org_study_id>
    <nct_id>NCT02329769</nct_id>
  </id_info>
  <brief_title>Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether PRO044 is safe and effective to use as medication&#xD;
      for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA&#xD;
      for the dystrophin protein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, open-label, extesion study. Following a Screening period of up to one month,&#xD;
      subjects previously treated with PRO044, and eligible for enrolment in PRO044-CLIN-02, will&#xD;
      be allocated to one of three groups to receive either 6 mg/kg or 9 mg/kg PRO044 weekly by IV&#xD;
      infusion or 6 mg/kg weekly by SC injection for 48 weeks.&#xD;
&#xD;
      Safety and tolerability, pharmacokinetics (PK), pharmacodynamic (PD) and efficacy assessments&#xD;
      will be conducted at regular intervals throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">July 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PRO044 (composite of several measures)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Efficacy parameters:&#xD;
Muscle Function&#xD;
6 Minute Walk Distance (6MWD)&#xD;
North Star Ambulatory Assessment&#xD;
Timed tests (10-meter walk/run, rising from floor, stair climb)&#xD;
DMD Functional Outcomes Questionnaire (DMD-FOS) -for ambulant subjects only&#xD;
Egen Klassification - for non-ambulant subjects.&#xD;
Muscle strength&#xD;
Pulmonary Function (Spirometry)&#xD;
Handheld myometry.&#xD;
Exploratory:&#xD;
Performance Upper Limb (PUL).&#xD;
Patient Reported Outcome measure (PROM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of PRO044 (treatement emergent adverse events)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Number of subjects with 1 or more treatement emergent adverse events following SC or IV PRO044 dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of PRO044 (composite of several measures)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Pharmacokinetic parameters:&#xD;
t ½&#xD;
AUC: 0-24h, 0-∞ (where applicable)&#xD;
Cmax&#xD;
tmax&#xD;
CL (for IV subjects) or CL/F (for SC subjects)&#xD;
PRO044 concentrations in muscle tissue.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>PRO044 SC 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly subcutaneous (SC) dosing with 6 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO044 IV 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly intravenous (IV) dosing with 6 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO044 SC 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly intravenous (IV) dosing with 9 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 SC 6 mg/kg</intervention_name>
    <arm_group_label>PRO044 SC 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 IV 6 mg/kg</intervention_name>
    <arm_group_label>PRO044 IV 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 IV 9 mg/kg</intervention_name>
    <arm_group_label>PRO044 SC 9 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects previously treated with PRO044.&#xD;
&#xD;
          2. Continued use of glucocorticoids for a minimum of 60 days prior to study entry with a&#xD;
             reasonable expectation that the subject will remain on steroids for the duration of&#xD;
             the study. Changes to the dose regimen or cessation of glucocorticoids will be at the&#xD;
             discretion of the Principle Investigator (PI) in consultation with the subject/parent&#xD;
             and the Medical Monitor. If the subject is not on steroids, involvement in the study&#xD;
             needs to be discussed with the medical monitor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current, or history of, liver or renal disease.&#xD;
&#xD;
          2. Acute illness within 4 weeks prior to the first dose of PRO044 (Week 1) which may&#xD;
             interfere with the measurements.&#xD;
&#xD;
          3. Severe cardiac myopathy which in the opinion of the Investigator prohibits&#xD;
             participation in this study&#xD;
&#xD;
          4. Need for daytime mechanical ventilation.&#xD;
&#xD;
          5. Screening aPTT above the upper limit of normal (ULN).&#xD;
&#xD;
          6. Screening platelet count below the lower limit of normal (LLN).&#xD;
&#xD;
          7. Use of anticoagulants, antithrombotics or antiplatelet agents.&#xD;
&#xD;
          8. Use of any investigational product within 6 months prior to the start of Screening for&#xD;
             the study.&#xD;
&#xD;
          9. Current or history of drug and/or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.Anna Hospital</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn- ochungdomssjukhus</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>BioMarin</keyword>
  <keyword>PRO044</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

